drugset

drugset / Trial / NCT06610526

A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease

NCT06610526 ↗

Phase 4 Active not recruiting 731 enrolled AstraZeneca

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to describe the efficacy and safety information with dapagliflozin in Chinese patients with chronic kidney disease.

Timeline

Start: 2024-08-23
Primary completion: 2027-05-31
Completion: 2027-05-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dapagliflozin	Small molecule	10 mg	Oral

Indications